Following the recent publication of the results of the COVA clinical trial (phase 2-3) in eClinicalMedicine (The Lancet), Biophytis organized a webcast to present the Group’s ambitions in the treatment of respiratory viral infections such as Covid-19 and influenza.
Biophytis announces the auditing of its 2025 financial statements and the resumption of trading in its stock
Biophytis announces the publication of its parent company financial statements for the fiscal year ended December 31, 2025, prepared in accordance with French accounting rules and principles and approved by…
